---
id: 197
title: Candida auris - Emerging Multidrug-Resistant Yeast
category: emerging_infections
subcategory: fungal
tags: [Candida-auris, C-auris, MDR, echinocandin, amphotericin, fluconazole-resistance]
difficulty: high
---

## Question

How is *C. auris* managed? Use **"MDR Yeast, Contact Precautions, Echinocandin (1st-Line), Resistance Common (Fluc 90%, Ampho 30%)"** framework.

## Answer

### ***Candida auris* Overview:**

**Emerging Pathogen:**
- **First identified:** 2009 (Japan), now worldwide
- **Multidrug-resistant** (MDR) yeast
- **Healthcare-associated** transmission (outbreaks in ICUs, LTACHs)
- **Difficult to identify** (misidentified as *C. haemulonii* by routine methods, requires MALDI-TOF or molecular)

**Resistance Patterns:**
- **Fluconazole:** 90-95% resistant
- **Amphotericin B:** 30-40% resistant
- **Echinocandins:** 5-7% resistant (increasing)
- **Pan-resistant strains:** Rare (~5%), but emerging

### **Clinical Manifestations:**

**Colonization (Most Common):**
- **Skin, axilla, groin**
- **Does NOT require treatment** (but infection control critical)

**Invasive Infections:**
- **Candidemia** (bloodstream infection) - most common
- **Intra-abdominal infection, urinary tract infection**
- **Wounds, surgical sites**

**Risk Factors:**
- **ICU admission, mechanical ventilation**
- **Central venous catheter**
- **Broad-spectrum antibiotics**
- **Diabetes, immunosuppression**
- **Recent surgery**

### **Diagnosis:**

**Culture:**
- **Blood culture, sterile site culture**
- **Requires specialized ID:** MALDI-TOF MS or molecular methods (PCR)
- **Misidentified by biochemical tests** (often called *C. haemulonii*)

**Screening (High-Risk Patients):**
- **Axilla/groin swabs** (detect colonization)
- **Indicated in outbreaks** or contacts of known cases

**Antifungal Susceptibility Testing:**
- **MUST perform** (resistance common, variable)
- **Send to reference lab** (CDC, state lab)

### **Treatment:**

**Candidemia / Invasive Infection:**

**First-Line:**
- **Echinocandin** (preferred)
  - **Micafungin 100mg IV daily**
  - OR **caspofungin 70mg IV × 1, then 50mg IV daily**
  - OR **anidulafungin 200mg IV × 1, then 100mg IV daily**

**Second-Line (Based on Susceptibilities):**
- **Liposomal amphotericin B 3-5 mg/kg IV daily** (if echinocandin-resistant or not tolerated)
- **High-dose fluconazole 800mg (12 mg/kg) IV/PO daily** (ONLY if fluconazole-susceptible, rare)

**Combination Therapy:**
- **Consider** for pan-resistant strains: **Echinocandin + liposomal amphotericin B** (anecdotal, no RCT data)

**Duration:**
- **14 days after last positive culture** + **resolution of symptoms**
- **Remove central venous catheter** if present

### **Infection Control (Critical):**

**Contact Precautions:**
- **Gown + gloves** upon room entry
- **Private room** or cohort (colonized/infected patients together)
- **Continue until discharge** (or multiple negative cultures if attempting decolonization)

**Hand Hygiene:**
- **Alcohol-based hand rub effective** (unlike *C. difficile*)

**Environmental Cleaning:**
- **Daily cleaning** with EPA-registered disinfectant (quaternary ammonium, bleach, hydrogen peroxide)
- ***C. auris* persists on surfaces** (weeks to months)
- **Enhanced terminal cleaning** (UV light, vaporized hydrogen peroxide)

**Screening:**
- **Axilla/groin swabs** for contacts of known cases (detect colonization)

**Colonization Management:**
- **Do NOT treat** colonization with antifungals (promotes resistance)
- **Strict infection control** to prevent transmission

### **Public Health Reporting:**

**Notify Public Health:**
- **ALL *C. auris* cases** (colonization OR infection) → reportable to CDC, state health department

### **Decolonization:**

**Not Routinely Recommended:**
- **No proven effective regimen**
- **Chlorhexidine baths** attempted (limited success)

## Key Points

### **MDR Yeast = Antifungal Resistance:**
- **Fluconazole:** 90-95% resistant (NOT first-line)
- **Amphotericin B:** 30-40% resistant
- **Echinocandins:** 5-7% resistant (first-line, but resistance increasing)
- **Pan-resistant:** Rare (~5%), use combination (echinocandin + amphotericin B)

### **Echinocandin = First-Line:**
- **Micafungin 100mg IV daily** (or caspofungin, anidulafungin)
- **Liposomal amphotericin B** if echinocandin-resistant

### **Contact Precautions:**
- **Gown + gloves, private room**
- **Persist on surfaces** (enhanced environmental cleaning essential)
- **Continue until discharge**

### **Do NOT Treat Colonization:**
- **Only treat invasive infection** (candidemia, sterile site infection)
- **Colonization = infection control, NOT antifungals**

### **MALDI-TOF or Molecular ID Required:**
- **Misidentified by routine biochemicals** (often called *C. haemulonii*)
- **If suspect *C. auris*:** Send to reference lab (CDC, state lab)

### **Clinical Pearls:**
- **MDR yeast:** 90% fluconazole-resistant, 30% amphotericin-resistant
- **First-line:** Echinocandin (micafungin, caspofungin, anidulafungin)
- **Contact precautions + enhanced environmental cleaning** (persists on surfaces)
- **Do NOT treat colonization** (promotes resistance)
- **Reportable to public health** (ALL cases - colonization + infection)
- **Require MALDI-TOF or molecular** for ID (misidentified by biochemicals)

## Sources

- [CDC: *C. auris* Guidelines 2024]
- [CID: *Candida auris* Management 2024]

## Media

N/A
